TY - JOUR T1 - Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00235-2019 VL - 53 IS - 5 SP - 1900235 AU - Dave Singh AU - Leonardo M. Fabbri AU - Massimo Corradi AU - George Georges AU - Alessandro Guasconi AU - Stefano Vezzoli AU - Stefano Petruzzelli AU - Alberto Papi Y1 - 2019/05/01 UR - http://erj.ersjournals.com/content/53/5/1900235.abstract N2 - In chronic obstructive pulmonary disease (COPD), exacerbation history is the strongest predictor of future exacerbation risk [1, 2]. Large cohort studies have shown that patients with one exacerbation in the previous year have an approximately two-fold increased future exacerbation risk compared to patients with no exacerbations, the risk increasing to five-fold in those with two or more exacerbations [1, 2]. Most clinical trials of pharmacological treatments designed to prevent exacerbations have therefore used the inclusion criterion of at least one exacerbation in the previous year, with a minority requiring at least two exacerbations [3–6].In patients with symptomatic COPD, severe/very severe airflow limitation, and a history of one moderate (and no severe) exacerbation, ICS-containing triple therapy significantly reduces exacerbation risk overall versus single or double maintenance therapy http://ow.ly/VgJC30o9pXCThe three studies described in this manuscript were funded by Chiesi Farmaceutici SpA, as were the analyses presented here. Writing support was provided by David Young of Young Medical Communications and Consulting Ltd. This support was funded by Chiesi Farmaceutici SpA. ER -